Tardive Dyskinesia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||1005828|
|出版日期||內容資訊||英文 117 Pages
|遲發性運動障礙治療的全球市場:成長，趨勢，COVID-19的影響，預測(2021年∼2026年) Tardive Dyskinesia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)|
|出版日期: 2021年04月21日||內容資訊: 英文 117 Pages||
The Tardive Dyskinesia Treatment Market is expected to register a CAGR of 4% during the forecast period. This is attributing to growing number of Schizophrenia Patients, rising incidences of neurological disorders. With prolonged use of antipsychotic drugs by schizophrenia patients, the chances of patients suffering from tardive dyskinesia are high. Thus high risk associated with growing number of antipsychotic drugs leading to promote the growth of the overall market. Tardive dyskinesia is an involuntary neurological movement disorder wherein there is an uncontrolled movement of body parts such as eyeballs, lips, and tongue. Moreover, the strong clinical trial pipeline for the treatment of tardive dyskinesia by several manufacturing companies is also boosting the market.
However, side effects of drugs lack awareness about the disorder and many undiagnosed cases may restrain the market to a certain extent.
VMAT Inhibitor is Expected to Witness a healthy Growth in Future
VMAT is expected to witness healthy growth in the future attributed to a growing number of neurological disorders and growing antipsychotic prescriptions. Several product approvals in VMAT inhibitors are promoting the growth of the market. For instance, in 2017 Neurocine biosciences got approval from the Food and Drug Administration (FDA) for a drug Valbenazine marketed under Ingrezza for the treatment of Tardive dyskinesia. In addition, Teva Pharmaceuticals drug name Austedo also gets approval. This results in driving the Tardive dyskinesia Treatment market.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Tardive Dyskinesia Treatment Market due to the increasing aging population, high prevalence of schizophrenia, increasing awareness, increasing healthcare expenditure and the presence of well-established healthcare infrastructure. As growing aging population will be leading to many diseases related to neurological for which this population has to take antipsychiatric drugs. Thus these populations are more prone to develop these diseases. Moreover, targeted patient pools such as populations treated with schizophrenia and bipolar disorder in this region are also associated with this disorder, hence promotes the growth of the tardive dyskinesia treatment market in this region.
The Tardive Dyskinesia Treatment Market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Teva Pharmaceutical Industries Ltd Neurocrine Biosciences, Inc, Sun Pharmaceutical Industries Ltd, SteriMax Inc., Lannett Co Inc, Sanis, and Allergan